| Market Capitalization (Millions $) |
46 |
| Shares
Outstanding (Millions) |
22 |
| Employees |
93 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-29 |
| Cash Flow (TTM) (Millions $) |
6 |
| Capital Exp. (TTM) (Millions $) |
0 |
Aileron Therapeutics Inc
Aileron Therapeutics Inc. is a clinical-stage biopharmaceutical company in the United States of America, founded in 200 The company is focused on the discovery, development, and commercialization of novel RNA-targeted therapeutics for cancer and other diseases. Aileron's proprietary platform technology, called Stapled Peptide Technology, enables the development of drug candidates that can selectively target intracellular and extracellular proteins.
Aileron's lead product candidate, ALRN-6924, is a first-in-class, dual MDM2/MDMX inhibitor for the treatment of solid tumors and hematologic malignancies. The drug works by restoring the function of tumor suppression proteins, p53 and p73, that are typically inactivated in cancer. ALRN-6924 is currently being evaluated in multiple phase 1 and 2 clinical trials for various types of cancer, including acute myeloid leukemia (AML), small cell lung cancer (SCLC), and tumors with p53-mutant alterations.
In addition to ALRN-6924, Aileron has a pipeline of drug candidates based on its Stapled Peptide Technology platform that are in various stages of preclinical development. These candidates target key intracellular and extracellular proteins involved in cancer, immunology, and other conditions.
Aileron has partnerships and collaborations with several leading pharmaceutical companies, including Roche, Lilly, and Celgene. These partnerships provide Aileron with access to resources and expertise to further advance its drug candidates and platform technology.
Aileron has a highly experienced management team and board of directors, with over 100 years of combined experience in drug development and commercialization. The company is headquartered in Boston, Massachusetts, and has a research and development facility in Cambridge, Massachusetts.
Overall, Aileron Therapeutics Inc. is a promising biopharmaceutical company dedicated to advancing novel RNA-targeted therapeutics for the treatment of cancer and other diseases. With a strong pipeline of drug candidates and partnerships with leading pharmaceutical companies, the company is well-positioned to make significant contributions to the field of oncology and beyond.
Company Address: 12407 N. Mopac Expy. Austin 78758 TX
Company Phone Number: 802-1989 Stock Exchange / Ticker: NASDAQ ALRN
|
0.4%